| Intrinsic Valuation of: SUNPHARMA | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 46 | Market Cap | ₹4,021B | |||||
| 2021 | - | - (-) | P/E Ratio | 36 | Total Asset | ₹921B | |||||
| 2022 | ₹75B | - (-) | Net Income | ₹109B | Total Debt | ₹25M | |||||
| 2023 | ₹29B | -61.6% (-65.9%) | EBITDA | ₹166B | Total Liab | ₹196B | |||||
| 2024 | ₹99B | 245.7% (213.2%) | Opr Margin | 0.24 | Debt/Equity | 0.00 | |||||
| 2025 | ₹119B | 20.2% (10.3%) | PreTax Margin | 23.60 | BV/Share | 226 | |||||
| 5Y Average FCF | ₹81B | 68.1% (52.5%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (25.0%) | ||||||||||
| 2026 | ₹149B | MBG Intrinsic Value | ₹409 | ||||||||
| 2027 | ₹187B | ||||||||||
| 2028 | ₹233B | ||||||||||
| 2029 | ₹292B | ||||||||||
| 2030 | ₹364B | ||||||||||
| 2031 | ₹456B | ||||||||||
| Terminal Value | ₹9,473B | Net Worth/Share | ₹302 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹7,421B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹103B | ₹3,136 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹25M | WACC | 7.3% | 2,732 | 2,946 | 3,205 | 3,524 | 3,926 | |||
| Equity Value | ₹7,523B | 7.4% | 2,707 | 2,917 | 3,170 | 3,481 | 3,873 | ||||
| Shares Outstanding | 2,399,330,048 | 7.4% | 2,682 | 2,888 | 3,136 | 3,439 | 3,821 | ||||
| 7.9% | 2,454 | 2,624 | 2,826 | 3,068 | 3,365 | ||||||
| DCF Intrinsic Value | ₹3,136 | 8.4% | 2,260 | 2,402 | 2,568 | 2,765 | 3,002 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||